Elevated Insights

From gene editing to biomanufacturing, learn more about the cell and gene therapy industry from our team of industry-leading experts

Featured Insights

// Oct 2026

Rethinking Release Testing: Building the Analytical Infrastructure for the Next Generation of Advanced Therapies

Adriana Geldart, Head of Technical Services

View Insight

// Sep 2026

Technology, Not Just Biology, Will Deliver the Future of Medicine

Mike Paglia, Chief Technology Officer

View Insight

// Aug 2026

Why the Traditional Approach to Evaluating Gene Editing is Not Your Only Option

By: Larry Lockwood, Chief Commercial Officer

View Insight

// Aug 2026

Partner Case Study: Accelerating CAR T-Cell Therapy Manufacturing for Autoimmune Disease

By: ElevateBio

View Insight

// Aug 2026

Targeted Gene Insertion Needs More Than One Tool

By: David Wiley, Director, Nucleic Acid Technology

View Insight

// Aug 2026

How Can AI-Directed Protein Engineering Improve Genomic Medicines?

By, Gavin Ellis, Senior Scientist, Translational Biology

View Insight

// Aug 2026

Can Lipid Nanoparticles (LNPs) Replace Electroporation for T-Cell Engineering?

By: Xiuying Li, Ph.D., Senior Scientist, Technology Development

View Insight

// Jul 2026

Rapid Release Testing Starts With Faster Contaminant Detection

By: Gary Sommerville Ph.D., Principal Scientist, NGS, Technical Services

View Insight

// Jul 2026

The Next Base Editors Will Be Engineered, Not Found

By, Matt Nethery, Principal Data Scientist, Computational Biology

View Insight

// Jul 2026

What Makes a Base Editor Potent and Specific Enough for Therapeutic SNP Correction?

By, Sean Crosson, Senior Scientist, Translational Biology

View Insight

// Jul 2026

Scaling Advanced Therapies and U.S. Biomanufacturing

View Insight

// Jun 2026

From Nature-Limited to AI-Designed: The Future of Gene Editing

By, Amy Pooler, Chief Scientific Officer and Matt Nethery, Principal Data Scientist, Computational Biology

View Insight

// Feb 2026

From Innovation to Impact: Building on Pittsburgh’s Legacy to Industrialize Advanced Therapies

Katie Shannon, VP, Site Head, BaseCamp Pittsburgh

View Insight

// Feb 2026

10 Questions to Ask When Choosing a Cell Therapy CDMO

Mike Paglia, Chief Technology Officer

View Insight

// Feb 2026

Why FDA Complete Response Letters Involve Manufacturing Issues – and What Must Change in Cell Therapy

By Cindy Riggins, Head of CMC Regulatory Affairs, ElevateBio

View Insight

// Nov 2025

Scaling Cell and Gene Therapies: Crossing the Inflection Point

By Mike Paglia, Chief Technology Officer, ElevateBio

View Insight

Capabilities & Services

Expertise

Elevated Insights

Featured Insights

Rethinking Release Testing: Building the Analytical Infrastructure for the Next Generation of Advanced Therapies

Technology, Not Just Biology, Will Deliver the Future of Medicine

Why the Traditional Approach to Evaluating Gene Editing is Not Your Only Option

Partner Case Study: Accelerating CAR T-Cell Therapy Manufacturing for Autoimmune Disease

Targeted Gene Insertion Needs More Than One Tool

How Can AI-Directed Protein Engineering Improve Genomic Medicines?

Can Lipid Nanoparticles (LNPs) Replace Electroporation for T-Cell Engineering?

Rapid Release Testing Starts With Faster Contaminant Detection

The Next Base Editors Will Be Engineered, Not Found

What Makes a Base Editor Potent and Specific Enough for Therapeutic SNP Correction?

Scaling Advanced Therapies and U.S. Biomanufacturing

From Nature-Limited to AI-Designed: The Future of Gene Editing

From Innovation to Impact: Building on Pittsburgh’s Legacy to Industrialize Advanced Therapies

10 Questions to Ask When Choosing a Cell Therapy CDMO

Why FDA Complete Response Letters Involve Manufacturing Issues – and What Must Change in Cell Therapy

Scaling Cell and Gene Therapies: Crossing the Inflection Point

Capabilities & Services

Expertise

Elevated Insights

Featured Insights

Rethinking Release Testing: Building the Analytical Infrastructure for the Next Generation of Advanced Therapies

Technology, Not Just Biology, Will Deliver the Future of Medicine

Why the Traditional Approach to Evaluating Gene Editing is Not Your Only Option

Partner Case Study: Accelerating CAR T-Cell Therapy Manufacturing for Autoimmune Disease

Targeted Gene Insertion Needs More Than One Tool

How Can AI-Directed Protein Engineering Improve Genomic Medicines?

Can Lipid Nanoparticles (LNPs) Replace Electroporation for T-Cell Engineering?

Rapid Release Testing Starts With Faster Contaminant Detection

The Next Base Editors Will Be Engineered, Not Found

What Makes a Base Editor Potent and Specific Enough for Therapeutic SNP Correction?

Scaling Advanced Therapies and U.S. Biomanufacturing

From Nature-Limited to AI-Designed: The Future of Gene Editing

From Innovation to Impact: Building on Pittsburgh’s Legacy to Industrialize Advanced Therapies

10 Questions to Ask When Choosing a Cell Therapy CDMO

Why FDA Complete Response Letters Involve Manufacturing Issues – and What Must Change in Cell Therapy

Scaling Cell and Gene Therapies: Crossing the Inflection Point

Footer